Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Vascular Permeability Factor, Etc.); Or Binds Serum Protein, Plasma Protein, Fibrin, Or Enzyme Patents (Class 424/158.1)
-
Publication number: 20150056212Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.Type: ApplicationFiled: October 28, 2014Publication date: February 26, 2015Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez
-
Publication number: 20150056204Abstract: The present invention includes apoptotic compositions and methods for inducing apoptosis of cancer cells independent of NK cells. An apoptotic composition comprises a cooperative combination of antibodies that specifically bind to human DR5, or a cooperative combination of an anti-DR5 antibody and TRAIL. Administration of therapeutically effective amounts of an apoptotic composition induces apoptosis of apoptosis sensitive cancer cells.Type: ApplicationFiled: March 27, 2013Publication date: February 26, 2015Inventors: Pamela Mary Holland, Jonathan David Graves, Jennifer Joy Kordich, Julia Catherine Piasecki, Ian Nevin Foltz
-
Publication number: 20150056216Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.Type: ApplicationFiled: November 10, 2014Publication date: February 26, 2015Inventors: MICHAEL SELA, YOSEF YARDEN, BILHA SCHECHTER, TSIPI BEN-KASUS
-
Publication number: 20150056200Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.Type: ApplicationFiled: June 30, 2014Publication date: February 26, 2015Inventors: Jasbir Seehra, Ravindra Kumar, Jennifer Lachey, Alan Koncarevic
-
Publication number: 20150056215Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing proliferative disorders, such as cancel-, that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include monotherapy with malate, or a derivative thereof, as well as combination therapy, such as malate, or a derivative thereof, combined with another therapeutic agent, such as a malic enzyme 2 inhibitor, an antineoplastic agent, a glycolysis inhibitor, an antiangiogenic agent, an immunomodulatory agent, an antibody, or a cytokine.Type: ApplicationFiled: April 4, 2013Publication date: February 26, 2015Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Vikas P. Sukhatme, Jian-Guo Ren
-
Publication number: 20150050237Abstract: The present invention relates to the field of anti-mycobacterial therapeutics, in particular the treatment of tuberculosis, especially including pulmonary multidrug-resistant tuberculosis (MDR-TB), with applications in extensively drug-resistant tuberculosis (XDR-TB) and extremely drug-resistant tuberculosis (XXDR-TB), preferably in combination therapy.Type: ApplicationFiled: March 13, 2013Publication date: February 19, 2015Inventors: Vasu Nair, Maurice O. Okello, Machhindra G. Gund, Byung I. Seo, Pankajkumar R. Singh, Naveen K. Mangu
-
Publication number: 20150050287Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.Type: ApplicationFiled: September 1, 2011Publication date: February 19, 2015Applicant: VACCINEX, INC.Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
-
Publication number: 20150050288Abstract: Methods for treating autoimmune disease using one or more inhibitor of STAT3 are provided herein. Also disclosed are methods for diagnosing and monitoring autoimmune disease or the propensity to develop autoimmune disease in a subject. The present invention demonstrates that inhibition of STAT3 prevents development of autoimmune disease in vivo. Based on this finding, Stat3 inhibitors can be used to treat and/or diagnose autoimmune disease in a subject.Type: ApplicationFiled: April 9, 2014Publication date: February 19, 2015Applicant: The Johns Hopkins UniversityInventors: Drew Pardoll, Charles Drake, Timothy Harris, Hua Yu
-
Publication number: 20150050289Abstract: Agents, compositions, and medicaments that pertain to modulating the activity of muscle specific kinase receptor (MuSK) and methods and uses thereof to modulate MuSK activity are encompassed herein. Also encompassed are screening assays to identify modulators of MuSK activity. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to alleviate or delay motor dysfunction in subjects afflicted with a disorder associated with nerve terminal loss or fragmentation, such as amyotrophic lateral sclerosis, sarcopenia, or anti-MuSK myasthenia gravis.Type: ApplicationFiled: November 14, 2012Publication date: February 19, 2015Inventor: Steven J. Burden
-
Publication number: 20150050216Abstract: The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment psoriasis in a subject.Type: ApplicationFiled: July 8, 2014Publication date: February 19, 2015Inventors: Mary Kaye Willian, Martin M. Okun, Rebecca S. Hoffman, Yihua Gu, Lisa E. Melilli, Kenneth B. Gordon, Subhashis Banerjee, Lori K. Taylor, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
-
Publication number: 20150050238Abstract: The present invention relates to the treatment of osteoarthritis and pain using IL-1? and IL-1? binding proteins, including anti-IL-1? and anti-IL-1? antibodies and engineered multivalent and multispecific IL-1? and IL-1? binding proteins.Type: ApplicationFiled: July 29, 2014Publication date: February 19, 2015Inventor: Rajesh V. KAMATH
-
Publication number: 20150050286Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.Type: ApplicationFiled: November 22, 2011Publication date: February 19, 2015Inventors: JAUME PONS, ARNON ROSENTHAL
-
Publication number: 20150050290Abstract: The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression.Type: ApplicationFiled: March 15, 2013Publication date: February 19, 2015Applicant: Universite Paris DescartesInventors: Ziad Mallat, Soraya Taleb, Alain Tedgui
-
Publication number: 20150050291Abstract: A method for detecting and/or monitoring a chronic inflammation condition associated with rheumatoid arthritis. The method comprises the steps of: (i) collecting a sample; (ii) detecting in the sample, one or more of a HMGN1 protein, a LCP-1 protein, a prtn3 protein, a sec22b protein, and a PYGL glycogen phosphorylase protein thereby producing a result; and (iii) correlating the result with a control. A test kit for diagnosing or monitoring a chronic inflammatory condition associated with rheumatoid arthritis. The test kit comprises an antibody for complexing with one of a HMGN1 protein, a LCP-1 protein, a prtn3 protein, a sec22b protein, and a PYGL glycogen phosphorylase protein.Type: ApplicationFiled: March 19, 2013Publication date: February 19, 2015Applicant: UNIVERSITYOF MANITOBAInventor: Neelhoffer Mookerjee
-
Patent number: 8956614Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: GrantFiled: June 15, 2010Date of Patent: February 17, 2015Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&DInventors: Bart De Strooper, Lujia Zhou, Wim Annaert
-
Patent number: 8956608Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.Type: GrantFiled: June 5, 2013Date of Patent: February 17, 2015Assignee: Wyeth LLCInventors: Frank S. Walsh, Margaret M. Zaleska, David S. Howland, Lioudmila Tchistiakova, Riyez Karim, Pamela Kelley, Xiang-Yang Tan, Seung Poon Kwak, Menelas N. Pangalos
-
Publication number: 20150044205Abstract: The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.Type: ApplicationFiled: August 11, 2014Publication date: February 12, 2015Applicant: GENENTECH, INC.Inventors: Brian Yaspan, Robert Royal Graham, Amy Dressen, Zhengrong Li, Erich Strauss, Teodorica Bugawan
-
Publication number: 20150044227Abstract: The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.Type: ApplicationFiled: March 7, 2013Publication date: February 12, 2015Inventors: Kari Alitalo, Simo Syrjala, Karl Lemstrom, Ching Ching Leow, Ronald Herbst, Jane Connor
-
Patent number: 8951521Abstract: An object is to provide a compound capable of inhibiting activation of TGF-? receptors due to HCV, and a screening method for the compound. It has been found that a HCV-derived NS3 protease binds to type I TGF-? receptor, and this binding results in activation of TGF-? receptors. Moreover, binding sites between the NS3 protease and type I TGF-? receptor were identified, and it has been found that antibodies recognizing these binding sites inhibit activation of TGF-? receptors due to NS3 protease. Furthermore, it has been also found that screening for a compound capable of inhibiting activation of TGF-? receptors can be performed by using the inhibition of the binding between NS3 protease and type I TGF-? receptor or the like as an index.Type: GrantFiled: August 30, 2011Date of Patent: February 10, 2015Assignee: RikenInventors: Soichi Kojima, Mitsuko Hara, Takehisa Matsumoto, Daisuke Takaya
-
Publication number: 20150037336Abstract: The present application relates to the combined use of an antigen-binding protein that binds HB-EGF and an EGFR tyrosine kinase inhibitor in medical treatment.Type: ApplicationFiled: February 20, 2013Publication date: February 5, 2015Applicant: U3 PHARMA GMBHInventor: Esther Zwick Wallasch
-
Publication number: 20150037347Abstract: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventor: Oleg llicch Epshtein
-
Publication number: 20150037349Abstract: The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against Tumor Necrosis Factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-Tumor Necrosis Factor-alpha polypeptides in treating inflammatory disorders, including rheumatoid arthritis. Compositions and methods for enhancing therapeutic potential of anti-Tumor Necrosis Factor-alpha polypeptides are provided, including linking the polypeptide to an albumin-binding domain and/or de-immunizing the polypeptide, to provide therapeutic agents with good solubility, enhanced serum half-life, and/or reduced immunogenicity, while substantially maintaining the specific binding properties of the anti-Tumor Necrosis Factor-alpha polypeptides.Type: ApplicationFiled: September 19, 2012Publication date: February 5, 2015Inventors: Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Rui Pedro da Silva Albuquerque e Freitas, Sara Ferreira Llorente Grancho Lourenço
-
Publication number: 20150037351Abstract: The present invention relates to an inhibitor of the P2Y2 receptor or an inhibitor of the P2Y2 receptor signaling pathway for use in preventing the metastasis of tumours or as a lead compound for developing a drug for preventing the metastasis of tumours.Type: ApplicationFiled: March 21, 2013Publication date: February 5, 2015Inventors: Stefan Offermanns, Boris Strilic, Dagmar Schumacher, Nina Wettschureck
-
Publication number: 20150037350Abstract: The invention provides means for treating Th1- and Th2-mediated diseases, such as asthma, allergic dermatitis and Th2-driven cancer. The invention extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment. The invention also extends to adjuvants and vaccines per se, and to their use in enhancing the immunomodulatory activity of immunogens.Type: ApplicationFiled: March 15, 2013Publication date: February 5, 2015Applicant: UCL BUSINESS PLCInventors: Anna L. Furmanski, Jose Ignacio Saldana, Tessa Crompton
-
Publication number: 20150037348Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: ApplicationFiled: July 10, 2014Publication date: February 5, 2015Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warner, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Du Fou
-
Publication number: 20150037248Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: ApplicationFiled: February 13, 2013Publication date: February 5, 2015Applicant: Agency for Science, Technology and ResearchInventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar, Florent Ginhoux, Pingyu Zhong
-
Patent number: 8945562Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: GrantFiled: November 1, 2013Date of Patent: February 3, 2015Assignee: True North Therapeutics, Inc.Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Publication number: 20150030609Abstract: The subject invention identifies CC chemokine ligand 20 (CCL20) as a novel biomarker for diagnosis of traumatic brain injury and/or neurodegeneration in the brain. The subject invention also provides treatment methods for traumatic brain injury and/or neurodegeneration in the brain by modulating systemic and/or brain-specific CCL20-CCR6 signaling. Also provided are uses of CCL20-CCR6 signaling a target for screening for therapeutic agents that are useful for treatment of traumatic brain injury.Type: ApplicationFiled: May 3, 2012Publication date: January 29, 2015Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Subhra Mohapatra, Shyam S. Mohapatra, Keith Ronald Pennypacker, Mahasweta Das, Christopher Charles Leonardo
-
Publication number: 20150030611Abstract: Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.Type: ApplicationFiled: October 7, 2014Publication date: January 29, 2015Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Michael Detmar, Kentaro Kajiya
-
Publication number: 20150030610Abstract: Disclosed herein are combinatorial therapies for treating or preventing reoccurrence of cancer. The therapies involve inhibition of LIMK1 in conjunction with taxane therapy. Specifically exemplified herein is co-administration of a LIMK1 RNA interfering molecule along with administration of a taxane.Type: ApplicationFiled: February 7, 2013Publication date: January 29, 2015Applicant: University of Central Florida Research Foundation, Inc.Inventor: Ratna Chakrabarti
-
Publication number: 20150030562Abstract: The invention provides a method of treating or preventing viral diseases in a mammal comprising administering to the mammal an interleukin (IL)-21 blocking agent in an amount effective to treat or prevent the viral disease in the mammal. Also provided is a method of reducing the activation or recruitment of immune cells in a mammal comprising administering to the mammal an IL-21 blocking agent in an amount effective to reduce the activation or recruitment of immune cells in the mammal. Methods of decreasing the expression of at least one cytokine or at least one protein in a mammal comprising administering to the mammal an IL-21 blocking agent in an amount effective to decrease the expression of the cytokine or the protein are also provided.Type: ApplicationFiled: December 21, 2012Publication date: January 29, 2015Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Warren J. Leonard, Rosanne Spolski
-
Publication number: 20150030612Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.Type: ApplicationFiled: October 10, 2014Publication date: January 29, 2015Inventors: William D. THOMAS, JR., Paul J. GIANNASCA, Zhenxi ZHANG, Wende LEI, Thomas P. MONATH
-
Patent number: 8940489Abstract: Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnotic agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.Type: GrantFiled: April 22, 2009Date of Patent: January 27, 2015Inventors: Hyun-Ju Doh, Doo-Sik Kim, Kwang-Hoe Chung
-
Patent number: 8940874Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.Type: GrantFiled: November 30, 2012Date of Patent: January 27, 2015Assignees: Wyeth LLC, MedImmune LimitedInventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
-
Patent number: 8940305Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: July 2, 2014Date of Patent: January 27, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8940299Abstract: A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell.Type: GrantFiled: March 2, 2009Date of Patent: January 27, 2015Assignee: Case Western Reserve UniversityInventors: M. Edward Medof, Michael G. Strainic, Young A Choi
-
Publication number: 20150023981Abstract: The present invention relates generally to a method of modulating graft functionality. More specifically, the present invention relates to a method of downregulating the onset or progression of graft dysfunction by downregulating the functional level of activin. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by graft dysfunction, such as the primary graft dysfunction associated with organ transplantation.Type: ApplicationFiled: May 17, 2013Publication date: January 22, 2015Applicant: PARANTA BIOSCIENCES LIMITEDInventors: David De Kretser, Robyn O'Hehir, Yi Chen
-
Publication number: 20150023982Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.Type: ApplicationFiled: September 26, 2014Publication date: January 22, 2015Applicant: AbbVie Biotechnology Ltd.Inventors: Steven A. FISCHKOFF, Joachim Kempeni, Roberta Weiss
-
Publication number: 20150023980Abstract: The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis A, B, C and other types of hepatitis, the diseases and conditions caused by HIV or associated with HIV, including AIDS.Type: ApplicationFiled: July 8, 2014Publication date: January 22, 2015Inventors: Oleg Iliich Epshtein, Sergey Alexandrovich Tarasov
-
Publication number: 20150017180Abstract: A method for the treatment of a chronic inflammatory condition in a patient which comprises administration to the patient of an agent which blocks or inhibits IL-3 signalling events in the patient.Type: ApplicationFiled: May 12, 2014Publication date: January 15, 2015Applicant: CSL LimitedInventors: Gino Luigi Vairo, John Allan Hamilton, Andrew David Cook
-
Publication number: 20150017183Abstract: Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described.Type: ApplicationFiled: December 20, 2012Publication date: January 15, 2015Inventors: Nabil G. Seidah, Jianbing Zhang
-
Publication number: 20150017182Abstract: The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.Type: ApplicationFiled: June 20, 2014Publication date: January 15, 2015Inventors: Leda MANNENT, Gianluca PIROZZI, Allen RADIN, Namita A. GANDHI, Robert EVANS
-
Publication number: 20150017157Abstract: The present disclosure relates to methods and materials for treating acne in a subject including, for example, moderate and/or severe acne, using anti-IL-1? binding molecules such as an anti-IL-1? antibody or binding fragment thereof.Type: ApplicationFiled: December 19, 2012Publication date: January 15, 2015Inventor: Paul Rubin
-
Publication number: 20150017179Abstract: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.Type: ApplicationFiled: May 19, 2014Publication date: January 15, 2015Inventors: Brett P. GIROIR, Monte S. WILLIS, Vidal F. DE LA CRUZ, JR., Thais M. SIELECKI-DZURDZ
-
Patent number: 8932591Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: May 15, 2012Date of Patent: January 13, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
-
Patent number: 8932592Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: GrantFiled: October 28, 2010Date of Patent: January 13, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Publication number: 20150010575Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.Type: ApplicationFiled: July 3, 2014Publication date: January 8, 2015Inventors: Bo Gyou KIM, Shangzi Wang, Ji Min Lee, Kyung Ah Kim, Louis M. Weiner
-
Publication number: 20150010574Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.Type: ApplicationFiled: June 13, 2014Publication date: January 8, 2015Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Paul ADAM, Eric BORGES
-
Publication number: 20150010477Abstract: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.Type: ApplicationFiled: September 15, 2014Publication date: January 8, 2015Inventors: Roland Martin, Henry McFarland, Bibiana Bielekova
-
Publication number: 20150010576Abstract: Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.Type: ApplicationFiled: July 10, 2014Publication date: January 8, 2015Applicant: Dana Farber Cancer Institute, Inc.Inventors: William G. Kaelin, JR., Mircea Ivan